Skip to main content

Posts

Showing posts with the label pandemic influenza

#Commentary: Preparing for the Next #Influenza #Pandemic: #Vaccine Progress, #Challenges, and Prospects

  Abstract Influenza pandemics arise when novel influenza virus subtypes emerge in populations with little or no pre-existing immunity . The recent expansion of H5N1 virus circulation in mammals — including documented spread in cattle and sporadic human infections — coupled with the emergence of mutations associated with enhanced pandemic potential , underscores the persistent threat of novel influenza strains. Pandemic preparedness critically depends on developing effective vaccines capable of providing broad protection across diverse viral strains. While vaccination remains the most effective strategy for preventing influenza and its complications, pandemic vaccine development faces substantial challenges . These include the rapid mutation rates characteristic of influenza viruses, driven by error-prone RNA replication, broad host range, environmental selection pressures, and frequent genetic recombination. Such factors complicate predictions of which strain will trigger the next...

#Influenza and Other Respiratory Viruses #Research #References (by AMEDEO, November 8 '25)

  Antimicrob Agents Chemother YAO B-F, Yang Y, Xu S-S, Tang B-H, et al Model-informed drug development in public health emergency of international concern: accelerating marketing authorization of simnotrelvir. Antimicrob Agents Chemother. 2025 Sep 18:e0061425. doi: 10.1128/aac.00614. PubMed           Abstract available LODISE TP, Min J, Nathanson BH, Yucel E, et al Comparison of early treatment with ceftolozane/tazobactam versus polymyxin-based therapy of pneumonia due to MDR Pseudomonas aeruginosa (PUMA). Antimicrob Agents Chemother. 2025;69:e0056925. PubMed           Abstract available DE LA PORTE DES VAUX C, Veyrenche N, Silva KD, Chavarot N, et al Immunocompromised patients with persistent SARS-CoV-2 viral shedding >/=8 weeks, clinical outcomes, and virological dynamics: a retrospective multicenter cohort study, 2020-2024. Antimicrob Agents Chemother. 2025 Sep 26:e0065825. doi: 10.1128/aac.00658....

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, October 1 '25)

  Arch Virol YIN Y, Chen J, Chen S, Huang J, et al The SARS-CoV-2 N protein disrupts G3BP1 function and alters lipid metabolism in COVID-19 pathogenesis. Arch Virol. 2025;170:237. PubMed           Abstract available Biochem Soc Trans CALL MJ, Call ME, Wu X Insights from deep mutational scanning in the context of an emerging pathogen. Biochem Soc Trans. 2025;53:1169-1179. PubMed           Abstract available BMC Pediatr VASQUEZ-LOARTE T, Guerra GA, Saldarriaga EM, Torres-Gomez L, et al Healthcare access satisfaction before and during the COVID-19 pandemic among Peruvian children with down syndrome. BMC Pediatr. 2025;25:874. PubMed           Abstract available Drugs SYED YY Clesrovimab: First Approval. Drugs. 2025;85:1487-1492. PubMed           Abstract available J Exp Med BISSETT C, Yong L, Spencer AJ, Ma FNL, et al Heterologo...

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, October 25 '25)

  Antiviral Res BESSONNE M, Morel J, Nevers Q, Groutsch J, et al Inhibition of influenza virus replication by artificial proteins (alphaReps) targeting its RNA-polymerase. Antiviral Res. 2025 Oct 21:106300. doi: 10.1016/j.antiviral.2025.106300. PubMed           Abstract available BMC Pediatr WONG K, Ducharme R, Murphy MSQ, Clarke AE, et al SARS-CoV-2 infection in pregnancy and infant outcomes in the first year of life: a retrospective cohort study. BMC Pediatr. 2025;25:842. PubMed           Abstract available MAGGIO ABR, Palomo S, Joye R, Huguet H, et al Reduced aerobic capacity in children with multisystem inflammatory syndrome in children (MIS-C) after PICU admission: a retrospective cohort study, 2020-2022. BMC Pediatr. 2025;25:835. PubMed           Abstract available Cell HICKMAN HD, Moutsopoulos NM Don't forget to floss! An innovative approach for vaccine del...

#Evolution of #antibody cross-reactivity to #influenza #H5N1 #neuraminidase from an N2-specific germline

  Highlights •  Human antibody HB420 cross-reacts with neuraminidases from H3N2 and H5N1 •  HB420 engages the neuraminidase active site via a single Asp residue •  Germline HB420 is N2 specific but gains reactivity to N1 through somatic mutation •  HB420 provides in vivo protection against both H3N2 and H5N1 Summary The ongoing spread of highly pathogenic avian influenza H5N1 clade 2.3.4.4b virus in animals and its occasional spillover to humans have raised concerns about a potential H5N1 pandemic . Although recent studies have shown that pre-existing human antibodies can recognize H5N1 neuraminidase , the molecular basis of how this cross-reactivity develops remains poorly understood. In this study, we used a phage display antibody library derived from 245 healthy donors to isolate an antibody , HB420, that cross-reacts with neuraminidases of human H3N2 and avian H5N1 clade 2.3.4.4b viruses and confers protection in vivo . Cryogenic electron microscopy analysis...

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, October 18 '25)

  Antiviral Res PATEL MC, Nguyen HT, Mishin VP, Pascua PNQ, et al Antiviral susceptibility monitoring: testing algorithm, methods, and findings for influenza season, 2023-2024. Antiviral Res. 2025 Oct 11:106299. doi: 10.1016/j.antiviral.2025.106299. PubMed           Abstract available ZHU C, Wang Z, Pan Z, Mai X, et al DMBT1 promotes SARS-CoV-2 infection and its SRCR-derived peptide inhibits SARS-CoV-2 infection. Antiviral Res. 2025 Sep 3:106269. doi: 10.1016/j.antiviral.2025.106269. PubMed           Abstract available TASHIMA R, Kuroda T, Nobori H, Miyagawa S, et al Ensitrelvir suppresses prolonged olfactory abnormalities derived from SARS-CoV-2 infection in hamsters. Antiviral Res. 2025 Sep 2:106270. doi: 10.1016/j.antiviral.2025.106270. PubMed           Abstract available BMC Pediatr WU LE, Wei JY, Lin ZH, Li HC, et al Clinical characteristics of children with ...

#Evolution of #WHO #Influenza #Antiviral #Stockpile: Rapid Access and Use in Low- and Middle-Income Countries for Pandemic Preparedness and Response

  Abstract The SARS outbreak and influenza A(H5N1) infections (2003–2004) prompted WHO to establish a global influenza antiviral stockpile , enabling rapid distribution to 72 countries during the 2009 A(H1N1) pandemic. To improve access in low- and middle-income countries, WHO added antivirals to the WHO Model List of Essential Medicines and included them in the Prequalification Programme . The 2011 Pandemic Influenza Preparedness Framework refined strategies for equitable access and rapid response. Lessons from COVID-19 led to a new WHO-led mechanism—the Interim Medical Countermeasures Network (i-MCM-net)— which supports integrated supply chains, real-time data sharing, research and development, and equitable access. WHO continues to emphasise equity and global solidarity , highlighting the need for accessible, effective, and affordable antivirals alongside vaccines to protect vulnerable populations and mitigate the impact of future pandemics. Source: Journal of Infectious Disease...

Introduction and Update: #Advances in #Influenza #Therapeutics

  Abstract This supplement contains 17 articles addressing various aspects of advances in influenza therapeutics and related strategies (e.g., diagnostics, rapid access strategies , and resistance monitoring ) for preventing and treating seasonal, zoonotic, and pandemic influenza . In addition to briefly introducing each article, we highlight shortcomings in current use, knowledge gaps requiring further study, and therapeutics of interest entering or advancing in clinical development. Source: Journal of Infectious Diseases,  https://academic.oup.com/jid/article/232/Supplement_3/S169/8287899?login=false ____